Brief: ContraFect Announces Award From Cystic Fibrosis Foundation To Evaluate Exebacase As A Potential Treatment For Serious MRSA Lung Infections Associated With Cystic Fibrosis
06/01/2022 22:33
Jan 6 (Reuters) - ContraFect Corp CFRX.O :
* CONTRAFECT ANNOUNCES AWARD FROM CYSTIC FIBROSIS FOUNDATION
TO
EVALUATE EXEBACASE AS A POTENTIAL TREATMENT FOR SERIOUS MRSA
LUNG INFECTIONS ASSOCIATED WITH CYSTIC FIBROSIS
Source text for Eikon: ID:nGNX1gkPzq
Further company coverage: CFRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CONTRAFECT
See all newsBrief: Contrafect Corp - On Nov 7, Co Received Delisting Notification From Nasdaq Hearings Advisor Stating That Panel Determined To Delist Co's Common Stock
Brief: ContraFect Says Selling Securityholder May Offer And Selling Up To 7 Mln Shares In Aggregate Of Common Stock
Brief: Contrafect Announces FDA Clearance Of CF-370 IND Application To Proceed With Phase 1 Clinical Study
Brief: Contrafect Corp Says On Sept 21, Notified By Nasdaq, That Co Not In Compliance With The Minimum Bid Price Requirement
Brief: Contrafect Announces Submission Of Ind Application To The FDA For Its Development Candidate Cf-370